期刊文献+

多取代吡啶酮衍生物的设计、合成及对DPP-Ⅳ蛋白酶的抑制活性 被引量:3

Design,Synthesis and Inhibitory Activities of Multi-Substituted Pyridone Derivatives on DPP-Ⅳ Protease
下载PDF
导出
摘要 通过分析alogliptin与DPP-Ⅳ蛋白酶的构效关系,通过骨架跃迁以及官能团互换,设计并合成出15个多取代吡啶酮类化合物,通过1HNMR和质谱确定了它们的结构,并对其进行了初步的体外酶活性筛选,得到了3个化合物11a、38、41与alogliptin活性相当的化合物,初步确立了该类化合物的DPP-Ⅳ酶构效关系。 By analyzing the structure-activity relationship of alogliptin with DPP-IV, the strategy of skeleton transition and functional groups swap was used to design and synthesize 15 multi-substituted pyridone compounds. And the structures of all the compounds were determined by 1^HNMR and ESI- Mass and three compounds 11a,38,41 which had quite similar activity to that of alogliptin were selected through preliminary activity screening in vitro, and the structure-activity relationships of these compounds with DPP-IVwere tentatively identified.
出处 《精细化工》 EI CAS CSCD 北大核心 2014年第10期1235-1244,1274,共11页 Fine Chemicals
关键词 糖尿病 DPP-1V抑制剂 阿格列汀 活性 吡啶酮衍生物 医药与日化原料 diabetes DPP-IV inhibitor alogliptin activity pyridone derivatives drug and cosmetic materials
  • 相关文献

参考文献10

  • 1Hollander P A, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors [ J ]. Postgraduate Medicine,2010,122 (3) : 71 - 80.
  • 2Hoist J J. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential [ J ]. Current Medicinal Chemistry, 1999,6 : 1005 - 1018.
  • 3Deacon C F,Holst J J,Carr R D. Glucagon-like peptide-1 :a basis for new approaches to the management of diabetes [ J ]. Drugs of Today, 1999,35 ( 3 ) : 159 - 170.
  • 4Zander M, Madsbad S, Madsen J L, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and fl-cell function in type 2 diabetes:a parallel-group study[J], The Lancet,2002,359 (9309) :824 - 830.
  • 5Gwaltney S L II, Stafford J A. Inhibitors of dipeptidyl peptidase 4 [ J ]. Annu Rep Med Chem, 2005 (40) : 149 - 165.
  • 6Zhang Z, Wallace M B, Feng J,et al. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidylpeptidase IV [ J ]. Journal of Medicinal Chemistry, 2011,54 ( 2 ) : 510 -524.
  • 7Liu Y,Ding Q,Wu X. Rearrangement of N,N-di-tert- butoxycarbonylpyridin-4-amines and formation of polyfunctional pyridines [ J ]. The Journal of Organic Chemistry, 2008,73 ( 15 ) : 6025 - 6028.
  • 8Deng J,Peng L,Zhang G,et al. The highly potent and selective dipeptidyl peptidase 1V inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes [ J ]. European Journal of Medicinal Chemistry,2011,46( 1 ) :71 -76.
  • 9Shibuya-Saruta H, Kasahara Y, Hashimoto Y. Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties [ J ]. Journal of Clinical Laboratory Analysis, 1996,10 (6) :435 - 440.
  • 10Feng J,Zhang Z,Wallace M B ,et al. Discovery of alogliptin:a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV [ J ]. Journal of Medicinal Chemistry, 2007,50(10) :2297 - 2300.

同被引文献20

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部